This phase II trial is evaluating a targeted cancer drug (Panitumumab) as a second line therapy for patients with advanced pancreatic ductal adenocarcinoma with wild-type KRAS mutation.
This trial is treating patients with pancreatic ductal adenocarcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Efficacy of Epidermal Growth Factor Receptor (EGFR) inhibitor Panitumumab for the treatment of KRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinoma
Other Non-Commercial Sponsor
This is a non-randomised trial and treatment allocation is not concealed. Patients will be screened and recruited into a treatment or an observation arm. In the observation arm of the study, two KRAS mutant patients undergoing alternative/standard second line chemotherapy will be enrolled for every one patient enrolled into the treatment arm. Following the enrolment of a patient in the treatment arm, the next two KRAS mutant patients who are both eligible and give consent will be selected for entry into the observation arm.
Recruiting Hospitals Read More